While routine adolescent female vaccination has been the foundation of intramuscular HPV vaccination programs since inception, gender-neutral policies and adult catch-up expansion are emerging as transformative strategies that maximize population impact, address health equity, and capture substantial market growth. Gender-neutral vaccination, where both males and females are targeted for routine immunization, has been adopted by over 38 countries by 2025, driven by recognition that HPV causes substantial disease burden in men including anal cancer, penile cancer, and oropharyngeal cancer, and that vaccinating males provides herd protection benefits that accelerate cervical cancer elimination. Australia's pioneering gender-neutral program, initiated in 2013, has achieved over 80% coverage for both sexes and demonstrated dramatic reductions in genital wart incidence across the entire population, not just vaccinated cohorts. The United States adopted gender-neutral recommendations in 2011, with Canada, the UK, and most Western European countries following suit. Over 45 million intramuscular HPV vaccine doses were administered to males globally in 2025, representing a substantial market expansion from female-only programs.

Adult catch-up vaccination for individuals aged 18-45 who were not vaccinated as adolescents represents another major expansion opportunity. Intramuscular Hpv Vaccination Market research indicates that the FDA's 2018 age expansion to 45 years for Gardasil 9, and subsequent payer coverage expansion, has created a large addressable market of approximately 80 million unvaccinated U.S. adults. However, adult uptake remains limited by low awareness of HPV-related cancers in men, cost concerns for uninsured individuals, and provider hesitancy to recommend vaccination to adults. Over 2.4 million adult intramuscular HPV vaccine doses were administered in the U.S. in 2025, representing significant growth potential as awareness campaigns and provider education improve.

Men who have sex with men represent a particularly important target population for adult vaccination, given their elevated risk of anal cancer and the limited herd protection benefits they receive from female-only programs. The UK's targeted program for men who have sex with men up to age 45, delivered through sexual health clinics, demonstrates effective targeted delivery models. Immunocompromised individuals, including HIV-positive persons and transplant recipients, experience higher rates of HPV-related disease and benefit from vaccination through age 45 regardless of sexual history. The integration of HPV vaccination into adult preventive care, including well-woman visits, men's health check-ups, and sexual health services, is expanding access points beyond traditional adolescent platforms. As gender-neutral policies become global standard, adult awareness increases, and targeted programs reach high-risk populations, the intramuscular HPV vaccination market is transitioning from adolescent female-focused intervention to universal population health strategy with substantially expanded addressable market and public health impact.

Q1: How many countries have adopted gender-neutral HPV vaccination? Over 38 countries had adopted gender-neutral policies by 2025, with Australia achieving 80%+ coverage for both sexes and demonstrating population-level genital wart reduction.

Q2: What is the adult catch-up market opportunity? The FDA's age expansion to 45 years creates an addressable market of approximately 80 million unvaccinated U.S. adults, with over 2.4 million adult doses administered in 2025 representing substantial growth potential.

Q3: Which adult populations are priority targets for HPV vaccination? Priority adult populations include men who have sex with men, immunocompromised individuals including HIV-positive persons, and all unvaccinated adults through age 45, with targeted delivery through sexual health and preventive care services.